A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Mild Type of Hand, Foot, and Mouth Disease

NCT ID: NCT01182532

Last Updated: 2012-07-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

3000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-05-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is aimed to evaluate the effectiveness and safety of traditional Chinese medicine (TCM) for treatment of hand, foot, and mouth disease (HFMD).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

By adopting a multi-center, randomized and controlled clinical trial, this study is aimed to evaluate the effectiveness, safety and economic evaluation of traditional Chinese medicine for treatment of HFMD, and to provide scientific evidence for the construction of TCM methods in treating HFMD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hand, Foot and Mouth Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Mild type of hand, foot and mouth disease Traditional Chinese Medicine Effectiveness Safety

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Western therapy

Group Type ACTIVE_COMPARATOR

Western therapy

Intervention Type OTHER

Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.

1. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;
2. Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;

TCM treatment

Group Type EXPERIMENTAL

TCM Syndrome Differentiation and Treatment

Intervention Type DRUG

1. Lung-Spleen Damp-Heat Syndrome Symptoms: Fever, maculopapule and herpes on hand, foot and buttock; herpes on oral mucous membrane; redness in throat, salivation, tiredness, faint red tongue or reddish tongue, greasy fur, speedy pulse, red and purple fingerprint.

Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Lonicera japonica Thunb (Jin Yin Hua), Scutellaria baicalensis Georgi (Huang Qin), etc.

Dosage: Adjusting by age and weight of patients. Decoction.
2. Dampness-Heat Retention Syndrome Symptoms: High fever, dirty color of tetter, tiredness, oral ulcer, reddish tongue or deep red tongue, little saliva, yellow and greasy fur, fine and rapid pulse, deep purple fingerprint.

Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Gardenia jasminoides Ellis (rough Zhi Zi), Scutellaria baicalensis Georgi (Huang Qin), etc.

Dosage: Adjusting by age and weight of patients. Decoction.

Western therapy plus TCM treatment

The combination of both western therapy and TCM treatment.

Group Type EXPERIMENTAL

Western therapy plus TCM treatment

Intervention Type OTHER

1. Symptomatic treatment using the same treatment methods in western therapy group;
2. Syndrome differentiation and treatment adopting the same methods in TCM treatment group.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Western therapy

Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.

1. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;
2. Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;

Intervention Type OTHER

TCM Syndrome Differentiation and Treatment

1. Lung-Spleen Damp-Heat Syndrome Symptoms: Fever, maculopapule and herpes on hand, foot and buttock; herpes on oral mucous membrane; redness in throat, salivation, tiredness, faint red tongue or reddish tongue, greasy fur, speedy pulse, red and purple fingerprint.

Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Lonicera japonica Thunb (Jin Yin Hua), Scutellaria baicalensis Georgi (Huang Qin), etc.

Dosage: Adjusting by age and weight of patients. Decoction.
2. Dampness-Heat Retention Syndrome Symptoms: High fever, dirty color of tetter, tiredness, oral ulcer, reddish tongue or deep red tongue, little saliva, yellow and greasy fur, fine and rapid pulse, deep purple fingerprint.

Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Gardenia jasminoides Ellis (rough Zhi Zi), Scutellaria baicalensis Georgi (Huang Qin), etc.

Dosage: Adjusting by age and weight of patients. Decoction.

Intervention Type DRUG

Western therapy plus TCM treatment

1. Symptomatic treatment using the same treatment methods in western therapy group;
2. Syndrome differentiation and treatment adopting the same methods in TCM treatment group.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of severe hand-foot-mouth disease patients according to Hand-Foot-Mouth Disease Treatment Guidelines 2010 issued by China's Ministry of Health; More than 1/3 patients should be diagnosed by etiological examination.
* Less than 48 hours of occurrence of fever and/or occurrence of tetter or herpes.
* Age of 1-14 years.
* Patients or their guardians agree to participate in this study and signed the informed consent form.

Exclusion Criteria

* Complicated with other serious primary diseases in organ such as congenital heart disease, chronic hepatitis, nephritis and blood diseases, etc.
* With history of allergies on traditional Chinese medicine.
* Patients or their guardians suffering from Psychiatric diseases.
* Attending other clinical studies on HFMD after diagnosed.
Minimum Eligible Age

1 Year

Maximum Eligible Age

14 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beijing University of Chinese Medicine

OTHER

Sponsor Role collaborator

China Academy of Chinese Medical Sciences

OTHER

Sponsor Role collaborator

The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Guoliang Zhang

Chief

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Guoliang Zhang

Role: PRINCIPAL_INVESTIGATOR

An'Hui Chinese Medical College Affiliated No.1 Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Anhui Provincial Children's Hospital

Hefei, Anhui, China

Site Status

The First Affiliated Hospital of Anhui College of Traditional Chinese Medicine

Hefei, Anhui, China

Site Status

Beijing Ditan Hospital

Beijing, Beijing Municipality, China

Site Status

Beijing You-An Hospital

Beijing, Beijing Municipality, China

Site Status

Chongqing Hospital of Traditional Chinese Medicine

Chongqing, Chongqing Municipality, China

Site Status

Fuzhou Infectious Disease Hospital

Fuzhou, Fujian, China

Site Status

Xiamen Hospital of Traditional Chinese Medicine

Xiamen, Fujian, China

Site Status

First Hospital of Lanzhou University

Lanzhou, Gausu, China

Site Status

Shenzhen Third People's Hospital

Shenzhen, Guangzhou, China

Site Status

The Fifth Hospital of Shijiazhuang, Hebei

Shijiazhuang, Hebei, China

Site Status

Wuhan Hospital for Infectious Diseases

Wuhan, Hubei, China

Site Status

Huhehaote Second Hospital

Hohhot, Inner Mongolia, China

Site Status

Ninth Hospital of Nanchang

Nanchang, Jiangxi, China

Site Status

Changchun Infectious Diseases Hospital

Changchun, Jilin, China

Site Status

Ningxia Hui Autonomous Region Forth People's Hospital

Yinchuan, Ningxia Hui Autonomous, China

Site Status

The Eighth Hospital of Xi'an City

Xi'an, Shaanxi, China

Site Status

Shanghai Public Health Center

Shanghai, Shanghai Municipality, China

Site Status

Chengdu Hospital for Infectious Diseases

Chengdu, Sichuan, China

Site Status

Xinjiang Hongxing Hospital

Urumuqi, Xinjiang, China

Site Status

First Affiliated Hospital to Kunming Medical College

Kunming, Yunnan, China

Site Status

The Sixth People's Hospital of Hangzhou

Hangzhou, Zhejiang, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

200907001-3

Identifier Type: -

Identifier Source: org_study_id